|Day's range||10.00 - 10.00|
In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
AbbVie (NYSE: ABBV) today announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 inhibitor. These moderate to severe plaque psoriasis patients previously had a suboptimal response to treatment with secukinumab or ixekizumab, both IL-17A inhibitor therapies, for at least six months before switching to risankizumab. The data were presented